Tau Therapeutics is a clinical stage biopharmaceutical company committed to providing patients with a better way of treating cancer through the development of calcium T-channel therapeutics.
Tau is the world leader in developing calcium T-channel products for the treatment of cancer and other indications. Tau’s novel, targeted Interlaced Therapy™ platform utilizes cell cycle synchronization technology and traditional chemotherapies to inhibit the growth of cancer cells. Ultimately, Interlaced Therapy™ magnifies the effects of chemotherapy on cancer cells while preserving healthy cells. It is Tau’s goal to usher in Interlaced Therapy™ as a new standard of care for all solid tumor cancers.
From the bench to the bedside, Tau is working diligently both to expand Interlaced Therapy™ to all solid tumor cancers and simultaneously further the development of its novel technologies and compounds.